Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation

NACompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 14, 2017

Study Completion Date

June 14, 2017

Conditions
Graft vs Host DiseaseCongenital AniridiaChemical BurnsStevens-Johnson SyndromeCongenital Glaucoma
Interventions
DEVICE

ARGOS-IO system

This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.

Trial Locations (2)

50924

Zentrum für Augenheilkunde der Universität zu Köln, Cologne

80637

MVZ Prof. Neuhann, Munich

All Listed Sponsors
lead

Implandata Ophthalmic Products GmbH

INDUSTRY

NCT02945176 - Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation | Biotech Hunter | Biotech Hunter